Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation

Diabetes Care. 2013 Dec;36(12):e201. doi: 10.2337/dc13-1690.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Review

MeSH terms

  • Blood Glucose / drug effects
  • DNA Mutational Analysis
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / genetics
  • Follow-Up Studies
  • Glyburide / therapeutic use*
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Infant
  • Insulin / therapeutic use*
  • Male
  • Mutation*
  • Potassium Channels, Inwardly Rectifying / genetics*
  • Potassium Channels, Inwardly Rectifying / metabolism
  • Sulfonylurea Compounds / therapeutic use

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Insulin
  • Kir6.2 channel
  • Potassium Channels, Inwardly Rectifying
  • Sulfonylurea Compounds
  • Glyburide